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Success with prevention of mother-to-child transmission (PMTCT) 
has resulted in a substantial reduction in the number of HIV-infected 
children.[1] Expanded access to antiretroviral therapy (ART), and 
recommen dations to start lifelong ART as soon as possible after diagnosis, 
have dramatically improved survival and reduced morbidity in HIV-
infected children and adolescents.[2] Current HIV treatment guidelines for 
children recommend a protease inhibitor (PI)-based regimen (lopinavir/
ritonavir (LPV/r)) in those ˂3 years of age and a non-nucleoside reverse 
transcriptase inhibitor (NNRTI)-based regimen in those >3 years old, 
combined with 2 nucleoside reverse transcriptase inhibitors (NRTIs).[3,4] 
In longitudinal follow-up studies, ~20% of children develop virolo-
gical failure (VF) 3 years after ART initiation.[5] In these children, 
associated drug resistance mutations (RMs) may occur in up to 90%. 
The most common mutations are associated with NNRTIs, lamivudine 
and thymidine analogues, with the lamivudine-associated mutation, 
M184V, occurring frequently.[6] In children on first-line PI regimens, 
detected NNRTI RMs would have been selected by PMTCT. 
In children, unique factors may result in poor adherence and/
or VF. These include exposure to nevirapine or efavirenz for 
PMTCT, with expected universal selection of NNRTI mutations 
in the exposed, and even modest rates of RMs in the unexposed (a 
reported rate of 24% in a PMTCT-unexposed population in South 
Africa (SA)).[7-9] Children are also caregiver dependent, and thus 
completely reliant on an adult for ART administration. Any social 
or financial instability or change threatens the sustainability of 
their treatment. Furthermore, there is poor palatability of certain 
paediatric antiretrovirals, particularly LPV/r, and in some cases lack 
of availability of paediatric formulations, which requires adaptation 
of adult formulations. Tuberculosis (TB) co-treatment is common, 
raising complexities of drug-drug interactions between rifampicin 
and LPV/r, which is used as first-line treatment in children. Failure 
to boost LPV/r, ideally with the addition of ritonavir, or worse still, 
in early HIV/TB a switch to ritonavir as a single PI with rifampicin-
based co-treatment (recommended by treatment guidelines at the 
time) has resulted in PI-associated RMs.[10,11] Adolescence is also 
a challenging time for adherence. The abovementioned factors 
possibly conspire to increase the risks of VF and resistance in 
children and adolescents compared with their adult counterparts. 
Virological failure in children 
In children with VF, if issues related to poor adherence can be 
addressed, and re-suppression is not achieved while on the current 
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regimen, a switch to a second- or third-line regimen may be indicated. 
Currently, children failing a first-line NNRTI-based regimen are 
switched to a PI-based regimen, which is fairly straightforward. More 
complicated is the scenario when children fail a first- or second-line 
PI-based regimen. Generally, PI-based regimens may allow lower 
adherence compared with an NNRTI-based regimen, as several 
mutations are required to confer resistance and rarely are selected, 
i.e. there is a high genetic barrier to resistance. The World Health 
Organization (WHO) recommends a switch from failing PI-based to 
NNRTI-based ART.[3] However, this alternative has not been studied 
well and should be further investigated. Resistance testing may be 
helpful to guide the further management and to select drugs that can 
be included in the next regimen. The clinical use of resistance testing 
depends on which drugs were included in the initial regimen and 
the availability of other agents. These second- or third-line regimens 
following PI-based ART usually include integrase strand transfer 
inhibitors (INSTIs), a PI (older or new generation) and possibly an 
NNRTI (new generation). In SA, atazanavir is routinely available 
for children >12 years of age and darunavir on a special application 
basis for children >3 years old. Children able to access these options 
generally do well clinically and virologically on third-line regimens.[3,12-14] 
Switching to a new susceptible regimen is the gold standard 
in managing children with VF. However, in the face of ongoing 
adherence challenges with potential accumulation of RMs, and 
limited treatment options due to extensive resistance and limited 
approved paediatric formulations, other strategies, such as continuing 
a failing PI regimen, switching to a holding regimen or discontinuing 
ART, have been used.[15,16] In comparative studies in the USA and SA, 
switching to a definitive regimen has been shown to have preferable 
virological and immunological outcomes than when children remain 
on their failing regimen, switch to a holding regimen or discontinue 
ART.[15,16] 
Holding regimens 
In cases where ongoing poor adherence is expected and there is 
concern regarding increased accumulation of RMs, or where few new 
drugs are available, strategies to ‘buy time’ while improving adherence 
have been employed. Holding regimens are defined as a switch to one 
or more NRTIs to provide some clinical and immunological benefit 
without the expectation of full viral suppression until adherence can 
be achieved and/or an alternative regimen can be obtained. Most 
commonly, lamivudine monotherapy is used as a holding regimen 
in children with known lamivudine resistance, on the premise that 
the lamivudine-associated M184V mutation reduces viral replication.[17] 
While this may be an option in certain situations, it should be used with 
caution and not as a default regimen in children who fail ART. Few 
data exist on the safety and efficacy of this holding regimen. Studies 
generally show immunological and sometimes clinical deterioration 
when this strategy is used. Studies from Johannesburg, the Eastern 
Cape and the multicentre International epidemiology Databases to 
Evaluate AIDS (IeDEA) cohort, reported a ≤25% decline in CD4+ 
count compared with time of switch after 6 months of lamivudine 
monotherapy in up to 72% of children, while in another study 8% 
of children deteriorated to WHO stage 3 or 4 disease.[18-20] The only 
randomised controlled study comparing lamivudine monotherapy 
with continuation of a failing PI-based regimen, IMPAACT P1094, 
enrolled 33 children and adolescents; it was discontinued owing to 
lack of accrual and delays in approval by ethics committees.[21] This 
study reported a >30% decline in CD4+ count in those receiving 
lamivudine monotherapy compared with those continuing a failing 
PI without clinical deterioration, leading to a recommendation by 
some guideline bodies that this strategy should not be routinely 
recommended.[21,22] Using additional NRTIs does not appear to 
mitigate CD4+ count decline. A study from New York, where child-
ren failing a PI-based regimen continued with ≥2 NRTIs, showed 
that at 48 weeks, there was a statistically significant decline in 
CD4+ count compared with baseline; however, there was no control 
group.[23] 
An additional concern with holding regimens that allow continuing 
viraemia is the possibility of increased risks of neurocognitive decline 
in children. HIV-infected children, even those who receive ART, 
have significant neurocognitive delay compared with their HIV-
unexposed and HIV-exposed uninfected counterparts.[24] In the 
context of planned treatment interruption in the Children with HIV 
Early Antiretroviral Therapy (CHER) trial, motor development was 
affected.[25] Nevertheless, with close observation and re-initiation 
of ART, recovery was possible (B Laughton – personal communi-
cation). The Paediatric European Network for Treatment of AIDS 11 
(PENTA 11) study found no neurocognitive deterioration with ART 
interruption.[26] In adults, treatment interruption is discouraged, 
largely based on the Strategies for Management of Antiretroviral 
Therapy (SMART) study, which found poorer outcomes in those 
who discontinued ART than in those who continued while being 
suppressed, attributable to unchecked inflammation and increased 
risk of cardiovascular disease.[27] In contrast, in children, no adverse 
clinical effects of short-term treatment interruptions have been 
observed. The reasons for halting the treatment interruption studies 
in children, such as in the OHP-03, have not been because of safety, 
but owing to low treatment interruption durability, i.e. futility of their 
intended purpose to lead to remission.[25,28,29] 
One of the motivations for the use of a holding regimen is to allow 
children and adolescents to practise adherence to their ART regimen. 
This may be advantageous, but may also introduce new adherence 
challenges and misunderstandings. For instance, children may 
misinterpret lamivudine monotherapy as a safe and easy regimen 
and may prefer it to ART. This could make it difficult to switch back 
to a suppressive regimen when necessary, based on immunological 
or clinical criteria. Children who receive lamivudine monotherapy 
also require intense clinical and adherence follow-up, including at 
least 3-monthly CD4+ count monitoring. This may be problematic 
for children who have socioeconomic problems at the heart of their 
poor adherence, where increased visits are simply not affordable. 
Ongoing enhanced adherence support is essential in these children 
and their families to enable an eventual switch back to a definitive 
ART regimen. An additional factor is that lamivudine monotherapy 
administered by less experienced clinicians may result in children 
and adolescents only accessing suppressive ART after severe clinical 
and immunological deterioration. Therefore, construing this option 
as safe for children may be misleading for clinicians and caregivers 
and should not be a default option in all children who fail ART, 
especially those failing second-line regimens. 
Recommendations for lamivudine 
monotherapy in children 
There are, however, specific situations where it may be necessary to 
consider a holding regimen. We propose the following inclusion criteria 
for recommending lamivudine monotherapy or holding regimens:
• Clinically well child (growth stable along centiles, no current or 
recent clinical disease expected to recur or re verse remission 
with immunological deterioration, including most WHO stage 4 
conditions, such as extrapulmonary TB, cryptococcal disease, 
Mycobacterium avium complex, lymphoma, Kaposi sarcoma 
and HIV-associated neurological disease). Children with proven 
previous pulmonary TB should be excluded. 
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• CD4+ count >30% and >500 cells/µL – to be checked 3-monthly.
• Able to attend the clinic for monthly follow-up.
• Able to conduct adherence counselling and support at each clinic 
visit. 
• Child should be >5 years old, unless there are no other options for 
treatment.
• Success of lamivudine treatment should be measured by a switch to 
a definitive ART regimen.
New regimens for children/adolescents 
There are problems with constructing new regimens for children with 
extensive resistance, which include challenges with regard to dosing 
and safety data for new ARVs, TB co-treatment, cost and availability. 
However, it is anticipated that newer drugs, such as dolutegravir, with 
a reduced side-effect and improved resistance profile, will be available 
in the next few years. It is hoped that these drugs will reduce the 
need for regimen switches in children with VF. Other new INSTIs, 
NNRTIs and PIs are currently being evaluated in phase I/II studies, 
as are improved formulations for delivery, such as injectable ARVs, 
including cabotegravir and rilpivirine. Research is also being done on 
therapeutic HIV vaccines and neutralising antibodies as treatment 
adjuvants. Investigation of new drugs in children is often delayed 
compared with that in adolescents and adults; often these studies do 
not include formulations palatable and easy to administer in children. 
However, over recent years there has been substantial progress in 
drug development, with numerous studies evaluating new ART in 
newborns, children and adolescents, making it likely that in the near 
future improved variety and efficacy of therapeutic options will be 
available for children. 
Conclusion
The management of VF in children is challenging. Improving 
adherence is the most important component. Key management 
points to consider are: minimising the accumulation of resistance 
mutations, ensuring that the child’s clinical condition remains stable, 
preventing new opportunistic infections or reversing remission of 
latent infections, and optimising growth and neurocognitive and 
educational development. Alternative options to fully suppressive 
ART should be used only in special circumstances, with substantial 
support, rather than as a default option.
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